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This manuscript presents a case of early stage squamous cell carcinoma of the left
buccal mucosa treated with intensity-modulated radiation therapy (IMRT) followed
by a high-dose rate (HDR) brachytherapy boost. With limited literature available
on HDR mold (stent) radiotherapy for oral cancer, a discussion on the issues en-
countered during treatment planning and delivery may prove to be insightful for
facilities faced with a similar challenge.
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I. INTRODUCTION
Squamous cell carcinoma of the buccal mucosa is relatively rare in the United States and West-
ern Europe and comprises approximately 10% of all carcinomas of the oral cavity.(1) For early
stage lesions, T1 and T2, treatment options include surgery or external beam radiation therapy
followed by a localized boost with an electron beam, interstitial implant, or intra-oral cone.(2)
Studies have shown radiation therapy to provide comparable results to surgery(3,4) with im-
proved cosmesis and function. Although brachytherapy has proven to be a viable treatment
option, the literature has focused on the use of interstitial brachytherapy.(4–7) Limited data is
available on high-dose rate (HDR) mold/stent radiation therapy for the treatment of oral cancer.(8)
This work presents a case of early stage squamous cell carcinoma of the left buccal mucosa
treated with intensity-modulated radiation therapy (IMRT) followed by an HDR brachytherapy
boost. The initial treatment was delivered with IMRT to spare the contralateral parotid and oral
cavity mucosa in order to prevent xerostomia and minimize acute mucositis.
II. METHODS AND MATERIALS
For this patient, the intention was to immediately follow IMRT (total dose of 60 Gy to the entire
buccal mucosa and 54 Gy to the ipsilateral neck nodes in 30 fractions over 6 weeks) with an
HDR boost to the left buccal mucosa. External beam radiotherapy was administered prior to
HDR to minimize the tumor’s thickness.
Prior to beginning the HDR course of treatment, it was necessary to create an applicator through
which the radioactive source could be transported. A custom acrylic radiation stent (density(9)
 
~ 1.19 g/cm3) was constructed prior to treatment in prosthodontics to conform to the patient’s
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lower jaw and attach to his teeth for fixation. The left central section of the stent was extended
laterally to minimize dose to the tongue and mandible. Four blind-ended catheters spaced ap-
proximately 5 mm apart were laid horizontally over this thickened portion of the stent to provide
uniform coverage to the tumor area. A spacing of 5 mm was selected to control the dose distribu-
tion delivered by this nonplanar stent and to ensure ample coverage in case of a compromised
catheter. The catheters were then covered by an additional 5 mm of acrylic to reduce the dose to
the mucosal surface. The stent was then modified to ensure a comfortable and reproducible fit.
Several adjustments were necessary before an adequate fit was achieved. This step was essential
to produce a fixed geometry applicator for which a pretreatment plan could be generated.
Once the applicator was constructed, the treatment was simulated by acquiring images of the
patient with the stent in place. A strand of dummy markers was inserted into each catheter. Each
strand consisted of a series of radio-opaque markers separated by a distance of 1 cm. The mark-
ers are used to mimic potential source positions in each catheter and assist with catheter
reconstruction. The treatment was simulated with both computed tomography (CT) and via
fluoroscopic images from the Nucletron® BV integrated brachytherapy unit. Although a CT-
based treatment plan was desired, the artifacts generated by the patient’s fillings and the dummy
markers rendered this technique challenging, at best. Due to time constraints, only the fluoro-
scopic images were utilized for treatment planning. A second CT scan of the stent alone in a
container of water was acquired to compare the dose distribution between the two simulation
modalities after the completion of treatment.
Treatment planning was performed with the Plato brachytherapy planning system version
14.2.5 (Nucletron® BV, Veenendaal, the Netherlands). A total dose of 10 Gy was to be deliv-
ered over the course of 5 days, in 2-Gy daily fractions, at a depth of 5 mm from the surface of
the stent. However, it was quickly realized that the surface of the stent could not easily be
discerned with two-dimensional imaging. As a result, a second set of fluoroscopic images of the
stent alone was obtained. Before these images were acquired, radio-opaque wires were posi-
tioned on the lateral surface of the stent directly over the position of each catheter and on the
inner surface of the stent to determine dose to tongue and mandible (Fig. 1). In addition, four
bee bees were affixed to the lateral surface of the stent to denote the anterior, posterior, superior,
and inferior extent of the lesion.
FIG. 1. Lateral and inner surface view of the custom-made stent. (a) Wires were placed over the position of each catheter
to define the lateral surface of the stent. Four bee bees were also positioned on the lateral surface to denote the anterior,
posterior, superior, and inferior extent of the lesion. (b) In addition, six shorter wires were placed on the inner surface of
the stent.
In the planning software, the four lateral wires were digitized as four additional catheters.
Dose points were placed 5 mm to the left of each dwell position in these “catheters.” The wires
along the inner surface of the applicator were digitized as marker points in order to determine
the maximum dose to the tongue and mandible. The four bee bees were also digitized as mark-
ers to monitor the dose along the circumference of the lesion. Lastly, applicator points were
placed 5 mm to the left of the tip, midsection, and anterior end of the central two “catheters”
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(lateral wires). The dose was prescribed to the applicator points (5 mm from the surface of the
stent), and to achieve the desired dose cloud around the catheters, the plan was optimized on
dose points. The plan was then fine-tuned by manually adjusting the weights of the individual
dwells to achieve an optimal dose distribution.
The last step in the treatment process was the actual delivery. The catheter lengths were
verified on the first day of treatment with a check ruler, and to ensure the integrity of the cath-
eters prior to each treatment, the inner core of each of the catheters was wiped. The detection of
fluid on the wipe was an indication of a compromised catheter. To verify the position of the
stent, semi-orthogonal images were acquired before each treatment and compared with in vivo
integrated brachytherapy unit images obtained during simulation.
Following treatment delivery, the axial CT images of the stent in water were imported into
the planning system. The stent was contoured and the catheters were reconstructed with the
assistance of anterior and lateral scout films. To compare the dose distributions of the fluoro-
versus the CT-based plan, the axes for both plans were centered on the anterior bee bee and
aligned such that the superior bee bee was intercepted in the y-z plane and the posterior bee bee
in the x-z plane. The average 3D deviation for the active sources between the two plans was
0.9 mm (maximum of 1.5 mm).
III. RESULTS
The design of the HDR stent was one of the key steps toward developing a successful treatment
plan. A custom stent was designed to fit comfortably and reproducibly within the patient’s mouth.
Several modifications were necessary before this was accomplished. One of the main issues that
arose during the construction of the stent was designing a common exit route for all four cath-
eters such that the patient did not accidentally clamp down and compromise any of the catheters.
This was an issue with the two most inferior catheters. In the early stent designs, the inferior
catheters were tucked under the stent, along the patient’s gum line. Thus, when the patient at-
tempted to place the stent, it did not fit securely within his mouth. To correct for this, the inferior
two catheters were repositioned so that they exited the stent with a steep superior curvature,
allowing them to exit laterally rather than along the patient’s gum line. However, during the first
day of treatment, the inferior-most catheter proved to be compromised. As a result, it was neces-
sary to modify the treatment plan to prevent the source from residing in this catheter. This required
adjusting the dwell weights in the remaining catheters to compensate for the compromised cath-
eter. Even with this restriction, the resulting treatment plan proved to be satisfactory (Table 1).
TABLE 1. Relative dose of the marker, applicator, and dose points based on the final, optimized treatment plan. The
dose is relative to the prescription dose (100% = 2 Gy). The marker points labeled “Wire n,” where n = 1–6, represent
the dose to the center of each of the shorter wires placed along the inner surface of the stent (see Fig. 1(b)). The dose
points listed are a sample of 60 that were placed 5 mm lateral to the surface of the applicator.
Marker points Dose (%) Applicator points Dose (%) Dose points Dose (%)
wire 1 121.85 tip catheter 2 106.07 1 105.88
wire 2 142.23 mid catheter 2 111.57 5 111.43
wire 3 187.87 ant catheter 2 103.91 10 107.57
wire 4 49.83 tip catheter 3 81.94 15 106.56
wire 5 68.61 mid catheter 3 101.47 20 88.88
wire 6 65.47 ant catheter 3 95.05 25 69.93
post bee bee 333.81 30 68.12
inf bee bee 96.82 35 111.56
sup bee bee 238.03 40 107.32
ant bee bee 150.70 45 101.36
50 101.47
55 94.62
60 85.98
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Following treatment delivery, a second treatment plan was generated from the CT scan of the
stent in water. Table 2 shows a comparison of the dose points using the two simulation modali-
ties. The dose to the wires in the CT plan was determined by entering the coordinates from the
fluoroscopic plan since the wires were absent during the second CT scan. Based on these re-
sults, the dose to the lesion was found to be hotter (up to ~16%), and the dose to the tongue and
mandible was found to be cooler (up to ~12.5%) than suggested by the initial fluoro-based plan.
Figure 2 depicts the dose distribution achieved by the CT plan.
  
FIG. 2. (a) Lateral and (b) posterior view of the reconstructed stent and 100% isodose cloud for the CT-based plan
TABLE 2. Comparison of dose points between the fluoro- and CT-based treatment plan
Dose point Fluoro plan dose (cGy) CT plan dose (cGy) D Dose (cGy) % Diff
post bee bee 668.98 754.36 85.38 12.76
inf bee bee 193.43 199.60 6.17 3.19
sup bee bee 474.47 549.35 74.88 15.78
ant bee bee 301.54 313.94 12.40 4.11
W1Ant 243.97 233.00 –10.97 –4.50
W1Post 243.47 235.06 –8.41 –3.45
W2Ant 273.66 263.03 –10.63 –3.88
W2Post 294.52 287.82 –6.70 –2.27
W3Ant 435.10 428.20 –6.90 –1.59
W3Post 317.61 277.98 –39.63 –12.48
W4Ant 89.36 89.17 –0.19 –0.21
W4Post 109.81 109.88 0.07 0.06
W5Ant 128.37 128.70 0.33 0.26
W5Post 146.02 145.77 –0.25 –0.17
W6Ant 145.80 143.61 –2.19 –1.50
W6Post 116.34 111.73 –4.61 –3.96
IV. DISCUSSION
Small squamous cell carcinomas of the oral cavity are ideally suited for localized radiation
therapy boost techniques, particularly in patients too ill for surgery or when surgical resection
would result in unacceptable functional and/or cosmetic deficits. Cancers of the anterior tongue,
floor of mouth, and buccal mucosa are especially amenable to localized boost techniques such
as intra-oral electron beam or orthovoltage cone therapy, low-dose rate interstitial brachytherapy,
or HDR interstitial brachytherapy.
Our patient had a 1.5-cm grade 1 clinical stage I (T1, N0, M0) squamous cell carcinoma
involving the left posterior and inferior aspect of the buccal mucosa. On palpation, it measured
less than 5 mm in thickness and did not directly involve the gingiva, buccal space, or masseter
muscle. Two independent surgical consultations suggested that surgical resection would have
included wide local excision of the buccal mucosa including the buccal space and outer cheek
skin, total parotidectomy, select neck dissection, and defect reconstruction using a radial fore-
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arm free flap.(10) The patient, who is a 47-year-old tile layer and drag racing mechanic and
enthusiast, was concerned about trauma to and function of his forearm after free flap harvest.
Therefore, after thorough evaluation and consultation in two multidisciplinary head and neck
cancer clinics, he elected to proceed with primary radiation therapy. Intensity-modulated radia-
tion therapy was utilized to treat the clinically uninvolved ipsilateral regional lymph nodes to
54 Gy in 30 fractions of 1.8 Gy per fraction while simultaneously treating the entire buccal
mucosa on the left with margin to 60 Gy in 30 fractions of 2.0 Gy per fraction. Intensity-modu-
lated radiation therapy was utilized to spare the contralateral parotid and submandibular glands
and the majority of the intra-oral mucosa. The patient tolerated this portion of the treatment
well with the expected grade 2 dermatitis, grade 3 mucositis, and altered taste.
High-dose rate stent brachytherapy was chosen for the localized boost technique because the
lesion was located posteriorly and inferiorly in the oral cavity. The use of orthovoltage radio-
therapy was briefly discussed but would require extraction of healthy teeth from the left mandible
to allow docking of the cone over the lesion with adequate margins; thus this modality was
dismissed as an option for this patient. A customized intra-oral stent would also be less invasive
and more comfortable for the patient when compared to interstitial implantation.
The HDR stent brachytherapy boost was administered as soon as the external beam radiation
therapy was completed without interruption. The primary tumor had completely resolved dur-
ing the external beam portion of the treatment, thus optimizing the HDR stent brachytherapy.
An impression of the primary tumor was made on the outer surface of the stent which aided in
treatment planning. The patient comfortably tolerated the 5 fractions of 2.0 Gy per fraction
HDR brachytherapy for a minimal total dose of 70 Gy in 35 fractions over 7 weeks despite the
localized mucositis from the external beam radiation therapy. Posttreatment biopsies of the
buccal mucosa at 6 weeks and 4.5 months have been free of cancer. The mucositis resolved
within 6 weeks of treatment completion. The patient’s taste has returned to normal, and there is
no xerostomia. The patient remains free of disease 10.5 months following treatment.
V. CONCLUSION
High-dose rate stent brachytherapy offers a great deal of promise for treating oral cancers. With
the limited literature available on HDR stent brachytherapy, the issues encountered during our
treatment planning and delivery process proved to be a good learning experience for our clinic
and may be useful for facilities faced with similar challenges.
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